VIRGINIA RETIREMENT SYSTEMS ET Al Purchases Shares of 295,711 Illumina, Inc. $ILMN

Key Points

• Virginia Retirement Systems acquired 295,711 Illumina shares worth approximately $52 million, while institutional investors collectively owned 89.42% of the company at quarter-end.
• Illumina exceeded quarterly expectations with $1.31 in EPS and $1.16 billion in revenue, up 9.4% year over year; Argus and RBC raised their price targets, though the analyst consensus remains “Hold” with a $191.31 target.
• Insider activity was notably negative: Director Keith Meister sold 457,858 shares for about $91.6 million, contributing to more than $436 million in insider sales over the past three months.

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 295,711 shares of the life sciences company's stock, valued at approximately $51,995,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned approximately 0.20% of Illumina at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ILMN. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter worth approximately $25,000. Fiduciary Financial Advisors bought a new position in shares of Illumina during the 2nd quarter worth approximately $26,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina during the 2nd quarter worth approximately $32,000. Quarry LP acquired a new stake in shares of Illumina during the 3rd quarter worth approximately $32,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Illumina in the 4th quarter valued at $33,000. Institutional investors own 89.42% of the company's stock.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 2,062,465 shares of company stock worth $436,589,802. 2.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research analyst reports. TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Barclays upped their price objective on shares of Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a report on Friday, July 31st. Royal Bank Of Canada increased their price objective on shares of Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Wall Street Zen upgraded Illumina from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Illumina in a research report on Monday, August 31st. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $191.31.

Illumina Stock Performance

Shares of ILMN stock opened at $218.22 on Monday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a fifty day simple moving average of $198.42 and a two-hundred day simple moving average of $159.33. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The firm has a market capitalization of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.